AOD-9604: the GH 176-191 lipolytic fragment that made it to Phase IIb trials — and what those trials actually showed.
AOD-9604 is a 16-amino-acid C-terminal fragment of human growth hormone (residues 176–191) developed by Metabolic Pharmaceuticals in Melbourne, Australia. It retains the lipolytic (fat-burning) activity of GH without stimulating GH receptor-mediated anabolic effects, IGF-1 elevation, or insulin resistance. It completed Phase IIb clinical trials for obesity. The trials showed modest weight loss that did not reach statistical significance at the primary endpoint — which explains why it never reached approval, and why the vendor narrative around this compound requires careful reading.
- C-terminal GH fragment (residues 176–191) with a disulfide bond between Cys 182 and Cys 189.
- Mechanism: stimulates lipolysis via β3-adrenergic receptor pathway; does not activate GH receptor or raise IGF-1.
- Rodent data: consistent fat mass reduction without affecting lean mass or insulin sensitivity.
- Phase IIb trials (METABOLIFE, Metabolic Pharmaceuticals): modest weight loss (~2–3 kg at 24 weeks) that did not reach statistical significance at the primary endpoint.
- GRAS (Generally Recognized as Safe) status was granted by FDA for food use — sometimes misrepresented as evidence of efficacy for weight loss.
- No anabolic or IGF-1-raising activity — key difference from full-length GH.
The GH lipolysis mechanism — separated from anabolism
Full-length growth hormone has two distinct metabolic activities that are mechanistically separable:
- GH receptor activation → IGF-1 → anabolic effects. GH binds the GH receptor, stimulates IGF-1 production, and drives protein synthesis and muscle growth.
- Direct lipolytic activity → fat mobilization. GH stimulates lipolysis in adipocytes independently of IGF-1 — via upregulation of hormone-sensitive lipase and β-adrenergic signaling. This activity is localized to the C-terminal region of the GH molecule.
AOD-9604 was engineered to retain only the second activity. It corresponds to the C-terminal lipolytic domain (residues 176–191) and lacks the N-terminal and central regions responsible for GH receptor binding and IGF-1 stimulation. Consequently, AOD-9604 in rodent models shows fat mass reduction without the IGF-1 elevation, insulin resistance, or acromegaly risk associated with full GH administration.
The rodent evidence
Preclinical evidence for AOD-9604 is consistent across several rodent models:
- Ng et al. (2000) showed that AOD-9604 reduced fat mass in obese mice by approximately 50% over 12 weeks without affecting lean mass or causing insulin resistance (PMID: 10917126).
- The lipolytic mechanism involves β3-adrenergic receptor stimulation in adipocytes, leading to activation of hormone-sensitive lipase and triglyceride hydrolysis — consistent with the fragment's proposed mechanism.
- No growth-promoting effects were observed — fat-free mass was unchanged, confirming the absence of IGF-1-mediated anabolism.
- Additional rodent studies examined cartilage repair and osteoarthritis models, finding some joint-protective effects — explaining why AOD-9604 is sometimes marketed for both fat loss and joint support (PMID: 24256678).
The Phase IIb trials — what actually happened
Metabolic Pharmaceuticals ran Phase IIb clinical trials (the METABOLIFE program) of oral AOD-9604 in overweight and obese adults. The trials are the most important context for evaluating vendor claims:
- Multiple dose levels were tested (1, 5, 10, 20, 30 mg/day orally) over 12 and 24 weeks.
- Results showed modest weight loss at all dose levels — approximately 2–3 kg at 24 weeks — but the difference from placebo was not statistically significant at the primary endpoint in the pivotal trial.
- The 1 mg/day dose outperformed some higher doses in some analyses — a dose-response pattern inconsistent with a simple pharmacological effect, complicating interpretation.
- Adverse event profile was favorable — no significant safety signals emerged, which led to FDA granting GRAS status for food use at low doses.
The GRAS designation is frequently misrepresented by vendors as proof of efficacy. GRAS means "safe at a given level in food products." It does not mean effective as a weight-loss compound. The Phase IIb failure on primary efficacy endpoints is the more relevant fact.
AOD-9604 vs. GLP-1 agonists: the comparison vendors avoid
In the contemporary obesity pharmacology context, AOD-9604's ~2–3 kg weight loss at 24 weeks compares unfavorably with GLP-1 agonists like semaglutide (~15% body weight loss at 68 weeks in the STEP-1 trial) and tirzepatide (~20% at 72 weeks). AOD-9604's lipolytic mechanism is pharmacologically interesting — and its favorable safety profile, including no insulin resistance or IGF-1 elevation, is a real advantage over full GH. But the magnitude of effect from the clinical trials does not support the marketing positioning as a significant anti-obesity compound by 2026 standards.